$256.59
-1.25%Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Quality against peers; 50 is the peer median.
Showing the last 4 periods. Pro adds the full annual and quarterly history and 20+ more metrics to chart.
The latest fiscal year and quarter, each against the same period a year earlier, from SEC filings.
Fundamentals: trailing twelve months to Dec 2025, from the latest 10-K and 10-Qs.
IM industry median · SM sector median: the typical company the value is compared with. The /100 is its score against those peers.
A reverse discounted-cash-flow model: the yearly growth in free cash flow over the next ten years that today's enterprise value pays for.
The price assumes less growth than the company has lately delivered.
The same assumptions for every company, so the figure compares expectations rather than valuing any one: a 9% discount rate, then 2.5% growth for ever after year 10, from the latest trailing free cash flow. Not shown for banks and insurers, or without positive free cash flow.
The companies closest in size in Biotechnology (filled from its sector when there are few), with the median and rank across all 571 in the industry.